API | vactosertib

vactosertib Report issue

Small molecule Experimental

Active Ingredient History

NOW

Now

Chemistry

SMILES: Cc1cccc(-c2[nH]c(CNc3ccccc3F)nc2-c2ccc3ncnn3c2)n1
InChIKey: FJCDSQATIJKQKA-UHFFFAOYSA-N
Mol. Mass: 399.43
ALogP: 4.24 Partition coefficient
ChEMBL Molecule:
vactosertib

More Chemistry

Pharmacology

Mechanisms of Action:
- TGF-beta receptor type-1 (Homo sapiens) ^UniProt
- Transforming growth factor beta-2 proprotein (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (8)

Research & Development (8)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (20)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (20)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Colorectal Neoplasms (Phase 1)

Esophageal Neoplasms (Phase 2)

Hematologic Neoplasms (Phase 1)

Hodgkin Disease (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Melanoma (Phase 2)

Multiple Myeloma (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Myeloproliferative Disorders (Phase 2)

Neoplasms (Phase 1/Phase 2)

Osteosarcoma (Phase 1/Phase 2)

Pancreatic Neoplasms (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Rectal Neoplasms (Phase 1)

Stomach Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 11
# of Trial Organizations: 8

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue